Edwards Lifesciences (NYSE:EW) today unveiled its “Stay in the Race” initiative to support heart valve health.

SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...

Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial ...

WASHINGTON, D.C.—A randomized trial of patients with a narrowing of their heart’s aortic valve, but who had not yet begun to show the symptoms of cardiovascular disease, demonstrated that replacing ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. At 7 years, there was no difference in clinical outcomes ...

Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences' Sapien 3 Ultra system. The artificial heart valve is pushed through the blood vessels via a catheter and ...

Edwards Lifesciences Corp.’s Sapien 3 platform has been approved for a new indication. The Food and Drug Administration recently cleared the line of catheter-based heart valves, which includes Sapien ...

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...